Form 4: BioMarin Director Barbara Bodem Receives Stock Grant

BioMarin Pharmaceutical Inc. director Barbara W. Bodem was granted 7,490 restricted stock units as part of equity compensation.

Summary

• Director Barbara W. Bodem acquired 7,490 shares of BioMarin Pharmaceutical Inc. (BMRN) common stock.
• The transaction occurred on June 2, 2026, in the form of a restricted stock unit (RSU) grant.
• The shares were granted at no cost ($0) as part of standard director compensation.
• Following this transaction, the director's total beneficial ownership increased to 21,045 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing routine director compensation rather than a signal of market sentiment or operational change.

Positives

• Alignment of director interests with shareholders through increased equity ownership.

Negatives

• None identified; this is a standard equity compensation event.

Risks

• None identified; this is a standard equity compensation event.

Future Outlook

Not applicable as this is a disclosure of a past equity grant.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard practice in the biotechnology sector to ensure long-term alignment between leadership and shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units to non-employee directors is consistent with standard corporate governance practices for mid-to-large cap pharmaceutical companies.

Stakeholder Impact

• Minimal impact on shareholders; reflects standard director compensation.

Next Steps

• No further actions required by the reporting person regarding this specific transaction.

Key Dates

Keywords

BioMarin, BMRN, Insider Trading, Form 4, Equity Compensation, Director Ownership